Form 4: Allogene Therapeutics Director Franz B. Humer Sells 11,200 Shares
SEC Form 4
Director Franz B. Humer sold 11,200 shares of Allogene Therapeutics, Inc. at an average price of $2.3376 on May 30, 2024.
Summary
- On May 30, 2024, Franz B. Humer, a director of Allogene Therapeutics, Inc., sold 11,200 shares of common stock.
- The shares were sold at a weighted average price of $2.3376, with individual transaction prices ranging from $2.31 to $2.37.
- Following the transaction, Humer directly owns 255,253 shares of Allogene Therapeutics common stock.
Sentiment
Score: 4
Explanation: The sentiment is neutral to slightly negative. While it's a routine transaction, insider selling can sometimes raise concerns among investors.
Negatives
- A director selling shares could be perceived negatively by investors.
Risks
- Insider selling activity can sometimes signal a lack of confidence in the company's future prospects, potentially impacting investor sentiment.
Industry Context
Insider trading activity is closely monitored in the biotech industry, as it can provide insights into the perspectives of company leadership regarding the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of the stock sale transaction |
| 06/03/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.